Neptune Technologies & Bioressources Inc., a nutrition products company, produces and commercializes nutraceutical products and turnkey solutions primarily for omega-3 softgel capsules and liquids. It offers specialty ingredients, such as MaxSimil, a patented ingredient that enhances the absorption of lipid-based nutraceuticals, and various other marine and seed oils, as well as pet supplements. The company's custom formulations are available in various delivery forms, such as softgels, liquid solutions, nutritional emulsions, and chewables. Neptune Technologies & Bioressources Inc. has an agreement with Tetra Bio-Pharma Inc. for the co-development, commercialization, and marketing of purified cannabinoid oil-based products to address pain and inflammation relief applications for the natural health products and pet veterinary markets. The company was founded in 1925 and is headquartered in Laval, Canada.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:NEPT
CUSIPN/A
Phone45-0687-2262
Debt
Debt-to-Equity RatioN/A
Current Ratio2.60
Quick Ratio2.08
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$21.56 million
Price / Sales15.75
Cash Flow$0.2323 per share
Price / Cash18.38
Book Value$0.86 per share
Price / Book4.97
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
EmployeesN/A
Outstanding Shares79,520,000
Market Cap$303.76 million
Neptune Technologies & Bioressources (NASDAQ:NEPT) Frequently Asked Questions
What is Neptune Technologies & Bioressources' stock symbol?
Neptune Technologies & Bioressources trades on the NASDAQ under the ticker symbol "NEPT."
How were Neptune Technologies & Bioressources' earnings last quarter?
Neptune Technologies & Bioressources Inc (NASDAQ:NEPT) posted its quarterly earnings results on Tuesday, August, 14th. The biotechnology company reported ($0.04) earnings per share for the quarter. The biotechnology company had revenue of $4.01 million for the quarter. View Neptune Technologies & Bioressources' Earnings History.
Who are some of Neptune Technologies & Bioressources' key competitors?
Some companies that are related to Neptune Technologies & Bioressources include Intra-Cellular Therapies (ITCI), Omeros (OMER), Retrophin (RTRX), Lexicon Pharmaceuticals (LXRX), Karyopharm Therapeutics (KPTI), Athenex (ATNX), Dicerna Pharmaceuticals (DRNA), Zai Lab (ZLAB), Vanda Pharmaceuticals (VNDA), Apellis Pharmaceuticals (APLS), Rhythm Pharmaceuticals (RYTM), Aptinyx (APTX), Eagle Pharmaceuticals (EGRX), Geron (GERN) and MacroGenics (MGNX).
Who are Neptune Technologies & Bioressources' key executives?
Neptune Technologies & Bioressources' management team includes the folowing people:
- Mr. James S. Hamilton, Pres, CEO & Director
- Mr. Mario Paradis, VP & CFO
- Mr. Marc Vaugeois, VP of Sales
- Mr. Michel Timperio, Pres of Cannabis Bus.
- Mr. François-Karl Brouillette, VP of Science & Innovation of Nutraceutical Bus.
Has Neptune Technologies & Bioressources been receiving favorable news coverage?
News coverage about NEPT stock has trended somewhat positive this week, Accern reports. The research group identifies positive and negative news coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Neptune Technologies & Bioressources earned a news and rumor sentiment score of 0.18 on Accern's scale. They also assigned news stories about the biotechnology company an impact score of 46.57 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near term. View Recent Headlines for Neptune Technologies & Bioressources.
Who are Neptune Technologies & Bioressources' major shareholders?
Neptune Technologies & Bioressources' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Alpine Global Management LLC (0.11%) and Bank of Montreal Can (0.05%).
Which major investors are selling Neptune Technologies & Bioressources stock?
NEPT stock was sold by a variety of institutional investors in the last quarter, including Alpine Global Management LLC.
Which major investors are buying Neptune Technologies & Bioressources stock?
NEPT stock was bought by a variety of institutional investors in the last quarter, including Bank of Montreal Can.
How do I buy shares of Neptune Technologies & Bioressources?
Shares of NEPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Neptune Technologies & Bioressources' stock price today?
One share of NEPT stock can currently be purchased for approximately $4.27.
How big of a company is Neptune Technologies & Bioressources?
Neptune Technologies & Bioressources has a market capitalization of $303.76 million and generates $21.56 million in revenue each year.
How can I contact Neptune Technologies & Bioressources?
Neptune Technologies & Bioressources' mailing address is 545 PROMENADE DU CENTROPOLIS SUITE 100, LAVAL A8, H7T 0A3. The biotechnology company can be reached via phone at 45-0687-2262 or via email at [email protected]
MarketBeat Community Rating for Neptune Technologies & Bioressources (NASDAQ NEPT)
MarketBeat's community ratings are surveys of what our community members think about Neptune Technologies & Bioressources and other stocks. Vote "Outperform" if you believe NEPT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NEPT will underperform the S&P 500 over the long term. You may vote once every thirty days.
